PMID- 22441004
OWN - NLM
STAT- MEDLINE
DCOM- 20130103
LR  - 20210204
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 18
IP  - 4
DP  - 2012 Jul-Aug
TI  - Podocyte as a potential target of inflammation: role of pioglitazone 
      hydrochloride in patients with type 2 diabetes.
PG  - 493-8
LID - 10.4158/EP11378.OR [doi]
AB  - OBJECTIVE: To observe the effects of pioglitazone hydrochloride on urinary 
      sediment podocalyxin and monocyte chemoattractant protein-1 (MCP-1) excretion in 
      patients with type 2 diabetes and to explore its possible renoprotective 
      mechanisms. METHODS: Ninety-eight patients with uncontrolled type 2 diabetes, who 
      were previously prescribed metformin, acarbose, or both, were randomly assigned 
      to a DP group (add-on pioglitazone; n = 49) or a DS group (add-on sulfonylurea; n 
      = 49). RESULTS: After 12 weeks of treatment, both add-on pioglitazone therapy 
      (the DP group) and add-on sulfonylurea therapy (the DS group) demonstrated a 
      similar improvement in fasting blood glucose and hemoglobin A1c, but systolic and 
      diastolic blood pressure declined significantly in only the DP group. Moreover, 
      the DP group showed significantly better efficacy in reducing urinary MCP-1 
      excretion in comparison with the DS group. Furthermore, both urinary albumin and 
      urinary sediment podocalyxin excretion decreased significantly in the DP group 
      but not in the DS group. The urinary sediment podocalyxin to creatinine ratio had 
      a positive correlation with urinary albumin to creatinine ratio (r = 0.624; 
      P<.01) and urinary MCP-1 to creatinine ratio (r = 0.346; P<.01). CONCLUSION: 
      Pioglitazone treatment revealed a podocyte-protective capacity in patients with 
      type 2 diabetes, and the underlying mechanisms may be partly attributed to its 
      effective suppression of excessive local renal inflammation.
FAU - Xing, Yan
AU  - Xing Y
AD  - Department of Endocrinology, Anhui Provincial Hospital, Hefei, Anhui, China.
FAU - Ye, Shandong
AU  - Ye S
FAU - Hu, Yuanyuan
AU  - Hu Y
FAU - Chen, Yan
AU  - Chen Y
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Protective Agents)
RN  - 0 (Sialoglycoproteins)
RN  - 0 (Thiazolidinediones)
RN  - 0 (podocalyxin)
RN  - 9100L32L2N (Metformin)
RN  - T58MSI464G (Acarbose)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Acarbose/therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Biomarkers/urine
MH  - Chemokine CCL2/urine
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/immunology/urine
MH  - Diabetic Nephropathies/immunology/*prevention & control
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Pioglitazone
MH  - Podocytes/*drug effects/immunology
MH  - Protective Agents/therapeutic use
MH  - Sialoglycoproteins/chemistry/urine
MH  - Solubility
MH  - Thiazolidinediones/*therapeutic use
EDAT- 2012/03/24 06:00
MHDA- 2013/01/04 06:00
CRDT- 2012/03/24 06:00
PHST- 2012/03/24 06:00 [entrez]
PHST- 2012/03/24 06:00 [pubmed]
PHST- 2013/01/04 06:00 [medline]
AID - S1530-891X(20)43059-9 [pii]
AID - 10.4158/EP11378.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2012 Jul-Aug;18(4):493-8. doi: 10.4158/EP11378.OR.